How many investments has Delos Capital made?

Delos Capital has 40 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.

What stage does Delos Capital invest at?

Delos Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does Delos Capital focus on?

Delos Capital focuses on Biotech, Healthtech, Medical Devices.

Where is Delos Capital located?

Delos Capital is headquartered in Cambridge, US.

Who does Delos Capital co-invest with?

Delos Capital most often shares deals with Ascension Ventures, New Enterprise Associates (NEA), Longitude Capital, among 45 tracked co-investors.

Delos Capital

Venture capital

Cambridge · Seed–Late Stage · 17 people tracked

Also known as DELOS ADVISORS LIMITED · DELOS ADVISORS, INC. · DELOS WEALTH ADVISORS, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Delos Capital

4,355 people in our graph share verified history with the Delos Capital team — schools, employers, funds. One of them is your warm intro.

Laura Buhlerunlockedknows Tej Pavoor · together at McKinsey & Company (overlapped)

×6knows the team · via Goldman Sachs

×2knows the team · via Harvard University

×2knows the team · via Agios Pharmaceuticals

knows the team · via Flagship Pioneering

✨ Fox Verdict

Investment thesis

Delos Capital invests in life sciences companies working to address disease and improve patient health. The firm seeks out exceptional science paired with strong founding teams pursuing medical breakthroughs. Drawing on a diverse skill set and a global network, the team supports ground-breaking innovations intended to improve lives worldwide.

Invests inBiotech Healthtech Medical Devices Cambridge China George Town Global United States

Source: firm website, verified Sep 15, 2026.

Stage

Seed–Late Stage

Cambridge, Massachusetts, US

Instruments

Equity

Founded

2014

Last 12 months

1 investment

AUM

$185.6M

VC funds

Tracked investments

IPOs

Team · 17 people

from the firm's website & curated & public directories

Henry Chen· Managing Partner· Hong Kongin

Henry Chen founded Delos Capital in 2014 and serves as its Managing Partner. He was previously a Partner and Co-Head of Asia at Permira, and earlier spent nine years at Goldman Sachs as a Managing Director and co-head of the General Industrials Group for Asia (ex-Japan), following corporate finance law work at Davis Polk. He has co-founded Curamir Therapeutics and Tulavi Therapeutics and served as CEO and Chairman of Tanvex BioPharma, and holds bachelor's and master's degrees from Harvard University and a JD from Harvard Law School.

h•••@deloscapital.comreveal

Tim Xiao· Partner· Hong Kongin

Partner and founding member of Delos Capital with 16 years in life science advisory and investing; leads investments and sits on or observes boards of numerous biotech and medtech companies. Previously spent seven years in investment banking, most recently at Goldman Sachs.

t•••@deloscapital.comreveal

Faris Lodin· Founder· Malaysiain 𝕏

Faris Lodin is the founder of AxeHoldings, where he builds and allocates capital across infrastructure sectors including AI and compute, cybersecurity, aerospace, biotech, and capital systems. He previously founded AxeInnovation, a technology platform that was acquired by Artroniq Berhad. Lodin also operates through Delos Capital and DarcMatter, focusing on long-horizon ownership in frontier technologies and strategic infrastructure.

Eric Huang· Partner, Ph.D.· Boston, Massachusetts, United Statesin

Eric Huang joined Delos Capital as a Senior Advisor in 2020, became an Operating Partner, and transitioned to full-time Partner in 2024. He previously held leadership roles at Moderna Therapeutics, including founding CSO of New Venture Labs, where he conceived the mRNA vaccine platform, and later served as GM and CSO at Moderna Genomics.

e•••@deloscapital.comreveal

Lee Cooper· Managing Director· Cambridge, Massachusettsin

Lee Cooper joined Delos Capital as a Managing Director in 2024, focused on advancing new medicines. He previously invested with Leaps by Bayer, founded a rare-disease genomic diagnostics company as an EIR at RA Capital, and worked on transactions at Moderna Therapeutics. He also lectures on bio-innovation at Tufts and Dartmouth.

l•••@deloscapital.comreveal

Tej Pavoor· Partner· Cambridge, USin

Tej Pavoor joined Delos Capital as a Partner in 2024, focusing on identifying and evaluating life sciences companies. He previously was an Operating Partner at Flagship Pioneering, served as COO of Laronde (now Sail), and spent nearly seven years at Moderna Therapeutics, concluding as SVP overseeing the clinical portfolio; earlier roles included McKinsey and Merck.

t•••@deloscapital.comreveal

Agnes Kwok· Financial Controller· Hong Kongin

Agnes Kwok is the Financial Controller at Delos Capital, based in Hong Kong, where she handles accounting, tax, reporting, and compliance since joining in 2018. She previously worked as Vice President in the Finance and Corporate Tax team at Bank of America Merrill Lynch for eight years and began her career at Ernst & Young focusing on banking, financial services, and asset management. She holds a BBA (Hons) in Accountancy from City University of Hong Kong and is a HK Certified Public Accountant and a member of The Institute of Chartered Accountants in England and Wales.

Andrea Lok· Executive Assistant· Hong Kongin

Andrea Lok joined Delos Capital in 2022 as the Executive Assistant for the firm's Hong Kong office. She previously worked as a secretary in the Corporate Legal Department at Nan Fung Group. She holds a Bachelor's in English for Professional Communications from City University of Hong Kong.

Carrie Greenaway· Office Operations, Boston Office· Bostonin

Carrie Greenaway joined Delos Capital in June 2024 and manages office operations for the firm's Boston office. She has over 15 years of operations experience spanning small startups to venture capital, most recently serving as Director of Finance and Operations at a Santa Monica-based event technology company. She holds a B.A. in International Relations from Saint Anselm College.

Paul Shen· Operations Manager· New Taipei City, New Taipei City, Taiwanin

Paul Shen joined Delos in 2022 as an Operations Manager. Before that, he spent 16 years working as an instructor and educator at five secondary schools and various test preparation centers. He holds a Bachelor of Arts from National Chung Hsing University and completed law extension courses at National Taiwan University.

Wynne Chan· Office Manager, Hong Kong Office· Hong Kongin

Wynne Chan is the Office Manager for Delos Capital's Hong Kong office, a role she has held since joining the firm in 2015. Before Delos Capital, she spent six years as Office Manager/Executive Assistant at Permira Advisers Limited and 14 years as an Executive Secretary in the Investment Banking Division of Goldman Sachs (Asia).

Adolfo Pena· Director

Dawn Griffiths· Director

John Collis· Director

William Heyland· Director

Hank Huang· Associate

h•••@deloscapital.comreveal

Yang Cheng· Associate, Ph.D.· Hong Kong, Hong Kong SARin

Yang Cheng joined Delos in 2022 as an Associate, bringing over ten years of experience in biomedical sciences. She was previously a drug discovery researcher at Boehringer Ingelheim focused on autoimmune diseases, holds a Ph.D. in Genetics from the University of Rochester, and a B.S. in Biology from Xiamen University.

y•••@deloscapital.comreveal

What they invest in

from 29 of 40 portfolio companies

Healthtech ×23Biotech ×21Medical Devices ×17Deep Tech ×5AI & Machine Learning ×3Digital Health ×2Hardware ×2Longevity ×2

HQs:United States×23Canada×1Singapore×1

Who they back

founder profiles across 15 portfolio companies

60%

solo founders

9 of 15 mapped founding teams

~3.5 yrs

old at investment

median across 8 dated deals

Founding team size:solo founder×92 founders×43 founders×14+ founders×1

Investments · 40 tracked

founders shown can be your intro path

By year:2026 · 1 2024 · 3 2023 · 3 2021 · 4 2020 · 1 2019 · 214 dated

Zenas Biopharmazenasbio.com inNASDAQ: ZBIO

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in

Board PATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsLongitude Capital New Enterprise Associates (NEA)Norwest Venture Partners Quan Capital SR One Capital Management Vivo Capital +1 more

Siriusrnasiriusrna.com✓ verified

Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.

BiotechHealthtechLongevityMedical DevicesSan Diego, US

Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)

Co-investorsOrbiMed Creacion Ventures

Tulavi Therapeuticstulavi.com in✓ verified

Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.

HardwareHealthtechMedical DevicesMountain View, US

Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)in Josh Vose(Chief Executive Officer)inCorinne Bright(Executive Officer, Director)

Board Henry Chen(Director)in

Co-investorsAscension Ventures

Verge Medical Aorto-ostial interventional technologiesostialflash.com✓ verified

Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.

HealthtechMedical Devices

Mike Buck(Chief Executive Officer)inAdam Tschida(General Manager & COO)in

Co-investorsAmed Ventures

▶︎ STRM.BIOstrm.bio in

STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients.

BiotechDeep TechHealthtechLongevityMedical Devices

Michael Luther(CEO)in

Co-investorsAscension Ventures Breakout Labs Breakout Ventures NYBC Ventures KdT Ventures

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen Horowitz Ascenta Capital General Catalyst Lightspeed Venture Partners Longitude Capital Lumira Ventures +9 more

AltruBioaltrubio.comMay 2024

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsaMoon RA Capital Biotechnology Value Fund Soleus Capital

Antios Therapeuticsantiostherapeutics.com in 𝕏Nov 2021 · $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)in Tamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling Capital Altium Capital Avego BioScience Capital Pontifax Venture Capital Amzak Health Domain Associates +8 more

Atia Accommodating intraocular lens replacementatiavision.com in

Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.

HardwareHealthtechMedical DevicesCampbell, US

Co-investorsAmed Ventures The Capital Partnership

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsForesite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed Quan Capital +3 more

Averna Therapeuticsavernatx.com in

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechHealthtechMedical DevicesWatertown, US

Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)

BoardRoy Amariglio(Director)Nick Olsen(Director)inStephen Squinto(Director)inMichal Silverberg(Director)in

Co-investorsDeep Insight Novartis Venture Fund OrbiMed

Baronovabaronova.com in

Non-surgical, non-pharmacologic devices to induce weight loss

Co-investorsLongitude Capital Arboretum Ventures Highland Capital Partners Sante Ventures

Cardurioncardurion.com inJul 2024 · $260M

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)in Michael Mendelsohn, M.D.(Founder)in

Co-investorsBain Capital Ascenta Capital Digitalis Ventures New Enterprise Associates (NEA)Bain Capital Life Sciences Bain Capital Tech Opportunities +4 more

Cloverbiopharmacloverbiopharma.com in 𝕏Mar 2026

Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.

BiotechHealthtechChengdu

Peng Liang(Executive Officer, Director, Promoter)in Joshua Liang(Executive Officer, Director)in

BoardXiaodong Wang(Director)

Curamir Therapeuticscuramirtherapeutics.comAug 2019

Woburn, US

LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)

Board HENRY CHEN(Executive Officer, Director)in

Curatia Interventional vascular productscuratiamed.com

Curatia Medical develops and manufactures FDA and CE-approved disposable medical devices for interventional procedures in cardiology, peripheral, neurology, and pulmonology.

Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US

Eccogeneeccogene.com inJun 2023

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.

BiotechHealthtechCambridge, US

Jingye Zhou(Founder)in

Co-investorsNew Alliance Capital

Ensomaensoma.comMay 2023 · $50M

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Albert Seymour(Director)

Board Kush Parmar(Executive Officer, Director)in Paula Soteropoulos(Director)Stephen Knight(Director)in

Co-investors5AM Ventures Aju IB Invesment Corporation Catalio Capital Management, LP F-Prime Capital Solasta Ventures Alexandria +7 more

Hemocorphemocorp.com in

Hemo Group develops interventional medical devices for treating neuro-vascular diseases, including ischemic stroke, hemorrhagic stroke, and neuro access, with products such as the Afentta intracranial thrombectomy device.

BiotechHealthtechMedical DevicesSingapore, SG

Imperativeimperative.com in 𝕏Jul 2021 · $260M

Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.

AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US

Aaron Hurst(Founder)in

Co-investorsVoyager Capital Ally Bridge Group Amed Ventures Ascension Ventures Bain Capital Life Sciences Catalio Capital Management +2 more

Imperative Care Incimperativecare.com in 𝕏

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.

HealthtechMedical DevicesCampbell, US

Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in

BoardJames Rogers(Director)Stacy Enxing Seng(Director)

Co-investorsAscension Ventures Bain Capital Life Sciences Catalio Capital Management, LP FemHealth Ventures Lightstone Ventures

Instylla Incinstylla.com in 𝕏

Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.

BiotechHealthtechMedical DevicesBedford, US

Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)inSteven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)in

Board Henry Chen(Director)in Tasneem Dohadwala(Director)in

Co-investorsAngel Physicians Fund Ascension Ventures Excelestar Ventures

Intrinsic Therapeuticsbarricaid.com in 𝕏

Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.

HealthtechMedical DevicesWoburn, US

Gregory H. Lambrecht(Director)Carey Hagan(Executive Officer, Director)Cary Hagan(Executive Officer, Director)

Board Ryan Drant(Director)inJeani Delagardelle(Director)Joshua Makower(Director)

Co-investorsNew Enterprise Associates (NEA)Questa Capital Greenspring Associates New Leaf Venture Partners

Liposeuticalsliposeuticals.com

Liposeuticals develops proprietary formulations of sterile injectable drugs for hospital use, focusing on anesthesiology, oncology, and infectious disease treatments.

BiotechMedical Devices

OncoMyx Therapeutics inDec 2021

BiotechPhoenix, US

Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)

Co-investorsB Capital Group Boehringer Ingelheim Venture Fund City Hill Ventures Korea Investment Partners Lumira Ventures LYZZ Capital +1 more

Phanestheraphanesthera.com

Phanes Therapeutics develops oncology and metabolic disease therapeutics targeting cell cycle regulators and related pathways.

BiotechDeep TechHealthtechMedical DevicesSan Diego, US

Dr. Ming Wang(Founder, President and CEO)

Rejonirejoni.com inSep 2020

Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.

BiotechFemTechHealthtechMedical DevicesBedford, US

AMARPREET SAWHNEY(Executive Officer, Director, Promoter)in Amar Sawhney(Founder)inNICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)

BoardTARA BUTLER(Executive Officer, Director, Promoter)

Co-investorsAscension Ventures ClavystBio FemHealth Ventures Iyengar Capital Partners Amed Ventures Catalyst Health Ventures

Rgenta Therapeuticsrgentatx.com inNov 2021 · $52M

Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)in Simon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)

Co-investorsVivo Capital AMR Action Fund Boehringer Ingelheim Venture Fund Korea Investment Partners Lilly Asia Ventures Matrix Capital Management +1 more

Trextrex.bio in

TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.

AI & Machine LearningBiotechDeep TechHealthtech

Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)

Co-investorsAvego BioScience Capital Pfizer Venture Investments Agent Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Allecra Therapeutics GmbHAntiosApamaApbioincLuqaOstialRenivaSyndaxTanvexThermalinTruvic

Exits · 1

1 IPOs

Zenas BiopharmaNASDAQ: ZBIO

Portfolio news

latest coverage across their companies

Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy

Ensoma · fiercebiotech.com · Aug 7, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Avenzo · geekwire.com · Jul 13, 2026

Rejoni Raises $25M to Prepare Uterine Healing Hydrogel for FDA Approval and Launch | Femtech Insider

Rejoni · femtechinsider.com · Jul 1, 2026

Sell or Invest in Tulavi Therapeutics Stock Pre-IPO

Tulavi Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026

Averna Therapeutics Announces Strategic Leadership Expansion

Averna Therapeutics · prnewswire.com · Mar 26, 2026

Imperative Care Raises $100M with Elevage and Perceptive Advisors to Advance Stroke Robotics Platform

Imperative · hlth.com · Mar 20, 2026

Intrinsic Therapeutics Announces Initial Release of Its Next Generation Barricaid Narrow Anchor Device Designed to Reduce Reherniation After Back Surgery

Intrinsic Therapeutics · prnewswire.com · Mar 4, 2026

A phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia | medRxiv

Curamir Therapeutics · medrxiv.org · Jun 9, 2025

Frequently asked questions

How many investments has Delos Capital made?: Delos Capital has 40 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.
What stage does Delos Capital invest at?: Delos Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Delos Capital focus on?: Delos Capital focuses on Biotech, Healthtech, Medical Devices.
Where is Delos Capital located?: Delos Capital is headquartered in Cambridge, US.
Who does Delos Capital co-invest with?: Delos Capital most often shares deals with Ascension Ventures, New Enterprise Associates (NEA), Longitude Capital, among 45 tracked co-investors.

Images

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

$100K – $15M